Omnitrope (Somatropin) is a recombinant human growth hormone indicated for the treatment of children with growth failure due to growth hormone deficiency (GHD), Small for Gestational Age, Prader-Willi Syndrome, Turner Syndrome and Idiopathic Short Stature. This is also used for treatment of adults with either adult onset or childhood onset GHD.
Where childhood onset growth hormone deficiency persists into adolescence, treatment should be continued to achieve full somatic development (e.g. body composition, bone mass etc). For monitoring, standardised to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity is one of the therapeutic objectives during the transition period. For guidance on dosing see adult section below. The attainment of a normal peak bone mass defined as a T score > -1.
Elderly patients may be more sensitive to the action of Omnitrope and therefore may be more prone to develop adverse reactions. A lower starting dose and smaller dose increments should be considered for older patients.
The 15mg cartridge cannot be used with the Omnitrope 10 or 5 pens. It is a larger size than normal and so needs to be injected using the surepal 15 injection device.
Important use of growth hormone is in the quest for remaining youthful. Many people want to reverse the lines and wrinkles on their face and have turned to growth hormone.